Last updated: August 23, 2026
SEPTRA is the historical brand name for sulfamethoxazole and trimethoprim, commonly abbreviated TMP-SMX. Its U.S. commercial trajectory is defined by mature generic competition, low pricing, broad clinical familiarity, and limited brand-specific financial disclosure. SEPTRA no longer has the commercial characteristics of a protected branded pharmaceutical. Market value resides in the active ingredient combination, manufacturing scale, hospital contracts, retail distribution, and product availability rather than in proprietary pricing.
The product remains clinically relevant for selected bacterial infections, including urinary tract infections, skin and soft-tissue infections caused by susceptible organisms, Pneumocystis jirovecii pneumonia, and certain gastrointestinal infections. Its financial outlook is stable but low growth, with periodic supply-driven price volatility.
What is SEPTRA and how does it compare with Bactrim?
SEPTRA is a brand associated with the combination of sulfamethoxazole and trimethoprim. Bactrim is the other major historical brand name for the same active ingredients.
| Product |
Active ingredients |
Common strengths |
Primary market position |
| SEPTRA |
Sulfamethoxazole/trimethoprim |
400/80 mg and 800/160 mg |
Historical brand; current branded availability is limited or market-specific |
| Bactrim |
Sulfamethoxazole/trimethoprim |
400/80 mg and 800/160 mg |
Historical reference brand |
| Generic TMP-SMX |
Sulfamethoxazole/trimethoprim |
400/80 mg, 800/160 mg; oral suspension |
Dominant U.S. supply base |
SEPTRA and Bactrim are therapeutically comparable when they contain the same strength and dosage form. The principal commercial distinction is branding and distribution. In current U.S. dispensing, pharmacies generally substitute generic sulfamethoxazole/trimethoprim unless a specific branded product is prescribed and available.
What is the FDA regulatory status of SEPTRA?
SEPTRA is associated with an approved sulfamethoxazole/trimethoprim product category, but the historical brand should not be treated as an actively protected branded franchise. Current U.S. supply is primarily generic.
The product is available in oral tablets and oral suspension formulations under generic labeling. Injectable formulations of sulfamethoxazole/trimethoprim also exist, although they are used in institutional settings and are not interchangeable with oral products.
FDA-approved uses have included:
- Urinary tract infections caused by susceptible organisms.
- Acute otitis media in selected patients.
- Exacerbations of chronic bronchitis.
- Shigellosis.
- Traveler’s diarrhea caused by susceptible organisms.
- Pneumocystis jirovecii pneumonia treatment and prophylaxis.
- Toxoplasmosis prophylaxis in selected clinical settings.
Clinical use is constrained by antimicrobial resistance, allergy risk, renal dosing requirements, hyperkalemia risk, drug interactions, and serious cutaneous reactions. The FDA labeling warns about Stevens-Johnson syndrome, toxic epidermal necrolysis, blood dyscrasias, hepatotoxicity, and kernicterus-related concerns in specific populations.[1]
When did SEPTRA lose exclusivity?
SEPTRA lost meaningful market exclusivity decades ago. Sulfamethoxazole/trimethoprim was introduced in the 1970s, and generic competition has existed for many years. There is no commercially meaningful remaining period of U.S. small-molecule patent exclusivity for the core combination.
| Exclusivity component |
SEPTRA position |
| New chemical entity exclusivity |
Expired |
| Core composition-of-matter protection |
Expired |
| Pediatric exclusivity |
Expired or historically irrelevant to current competition |
| Orphan exclusivity |
None applicable to the core product |
| Active U.S. brand exclusivity |
No meaningful current protection |
| Generic substitution |
Broadly established |
Exact patent-expiration analysis is less commercially useful for SEPTRA than for newer medicines because the relevant compound and formulation rights expired before the modern generic market became the primary supply channel.
What patents protect SEPTRA today?
No high-value, commercially decisive patent estate is generally associated with the core SEPTRA combination in the U.S. market. Historical patents covering sulfamethoxazole, trimethoprim, their combination, or conventional oral dosage forms are expired.
Current intellectual-property barriers are more likely to involve:
- Manufacturing processes.
- Crystalline or polymorphic forms.
- Excipients and suspension stability.
- Packaging and container-closure systems.
- Institutional injectable formulations.
- Narrow formulation patents in non-U.S. markets.
These rights do not recreate the original brand franchise. A formulation patent could affect a particular product presentation, but it would not ordinarily block generic manufacturers from selling standard sulfamethoxazole/trimethoprim tablets or suspension using noninfringing technology.
Are there formulation patents for SEPTRA?
Standard immediate-release tablets and oral suspensions have been commercially available for many years. Any surviving formulation rights would need to be assessed product by product and jurisdiction by jurisdiction. The economic impact is limited because several manufacturers can supply standard dosage forms.
The main technical barriers are regulatory consistency and manufacturing reliability. Generic manufacturers must control:
- Active-ingredient assay and impurity profiles.
- Content uniformity.
- Dissolution performance.
- Suspension sedimentation and redispersibility.
- Microbiological quality.
- Stability through the labeled shelf life.
- Bioequivalence where applicable.
These requirements create compliance costs, but they are not equivalent to patent exclusivity.
How many patents cover SEPTRA?
The number of historically associated patents may vary depending on whether the search includes expired patents, foreign patents, manufacturing patents, and patents directed to unrelated uses. The commercially relevant answer is that no known active core patent portfolio materially prevents generic U.S. entry.
Patent searches should distinguish among:
- Expired composition patents.
- Expired combination patents.
- Formulation patents.
- Manufacturing-process patents.
- Use patents for specific infectious-disease indications.
- Foreign rights with no direct U.S. market effect.
Because SEPTRA is a mature generic product, a raw patent count would overstate the strength of its current exclusivity position.
What is the Orange Book status of SEPTRA?
The FDA Orange Book records approved drug products and patent or exclusivity information relevant to approved applications. For mature sulfamethoxazole/trimethoprim products, the important commercial fact is the absence of a current core patent barrier that would prevent ANDA competition.
SEPTRA’s Orange Book significance is therefore historical and regulatory rather than defensive. The relevant questions for a current competitor are:
- Which sulfamethoxazole/trimethoprim products have active approvals?
- Which dosage forms remain commercially supplied?
- Are any listed patents still active?
- Is the reference product available for bioequivalence comparison?
- Do manufacturing-site or supply disruptions affect substitution?
The Orange Book should be checked against the specific NDA or ANDA number because brand names can persist in commercial references after a particular branded presentation is discontinued or transferred.[2]
Are there Paragraph IV challenges involving SEPTRA?
Paragraph IV litigation is not a central current risk for SEPTRA. The product’s core patents are old, and generic entry occurred long ago. Any modern ANDA filing would more likely rely on an established generic pathway without confronting a commercially meaningful, unexpired composition patent.
Potential disputes could still arise around:
- A newly developed delivery system.
- A reformulated suspension.
- An injectable product.
- A proprietary combination with another active ingredient.
- Manufacturing or labeling rights.
Those disputes would concern a specific product or presentation rather than the mature SEPTRA franchise.
What is SEPTRA’s current market size?
SEPTRA-specific revenue is not separately disclosed by major public pharmaceutical companies in a way that supports a reliable standalone market-size estimate. Generic manufacturers usually report broad portfolios, therapeutic areas, or total generic revenue rather than sales by mature antibiotic molecule.
The product’s economic profile can be summarized as follows:
| Financial variable |
SEPTRA assessment |
| Revenue visibility |
Low at the individual brand level |
| Unit demand |
Persistent, supported by common outpatient and hospital use |
| Average selling price |
Low in routine tablet markets |
| Margin profile |
Sensitive to manufacturing scale and contract pricing |
| Growth rate |
Mature to declining in nominal terms, with periodic volume shifts |
| Competitive intensity |
High |
| Pricing power |
Minimal |
| Supply-chain sensitivity |
Moderate to high |
| Brand premium |
Limited |
Generic TMP-SMX generates recurring but fragmented revenue. Volume comes from routine prescriptions, prophylaxis, hospital use, long-term-care facilities, and public-sector purchasing. Revenue does not generally depend on a branded marketing campaign.
What drives SEPTRA market demand?
Demand is influenced by clinical guidelines, local resistance patterns, patient allergy profiles, and the availability of alternative antibiotics.
Important demand drivers include:
- Continued use in uncomplicated and complicated urinary tract infections when susceptibility supports treatment.
- High-value use in Pneumocystis jirovecii pneumonia treatment and prophylaxis.
- Use against community-associated methicillin-resistant Staphylococcus aureus in selected cases.
- Low acquisition cost relative to many newer antibiotics.
- Familiar dosing and broad generic availability.
- Use in outpatient settings, where oral therapy reduces administration costs.
Demand is constrained by rising resistance among some pathogens, increasing use of alternative agents, safety concerns, and changes in antimicrobial stewardship policy. Infectious-disease guidelines generally require clinicians to consider organism susceptibility rather than treating TMP-SMX as a universally appropriate empiric antibiotic.[3]
How does antimicrobial resistance affect SEPTRA’s financial trajectory?
Resistance creates a mixed commercial effect. It reduces use in infections where susceptibility is unreliable, but the product remains valuable in indications where it retains strong activity or where alternatives are more expensive.
For urinary tract infections, local resistance rates can determine whether TMP-SMX is appropriate for empiric treatment. For Pneumocystis jirovecii pneumonia prophylaxis and treatment, the combination remains an important low-cost option, although tolerability and patient-specific risk factors affect selection.
The financial result is a gradual shift from broad empiric use toward targeted use. That limits volume growth but preserves a durable base of demand.
Which companies compete with SEPTRA?
Competition comes from both generic TMP-SMX manufacturers and alternative antibiotics.
Generic competitors
The U.S. generic market has included manufacturers such as:
- Amneal Pharmaceuticals.
- ANI Pharmaceuticals.
- Hikma Pharmaceuticals.
- Dr. Reddy’s Laboratories.
- Teva Pharmaceuticals.
- Rising Pharmaceuticals and other contract or specialty suppliers.
Supplier participation changes over time because of product discontinuations, manufacturing transfers, shortages, and portfolio rationalization. No single manufacturer generally controls the entire U.S. market.
Therapeutic competitors
Depending on indication, alternatives may include:
- Nitrofurantoin.
- Fosfomycin.
- Fluoroquinolones.
- Beta-lactam antibiotics.
- Doxycycline or clindamycin for selected skin infections.
- Atovaquone or pentamidine in Pneumocystis jirovecii pneumonia settings.
SEPTRA’s competitive advantage is usually cost and familiarity. Its disadvantages are resistance, adverse-effect risk, and clinically important interactions.
What generic entry risks exist for SEPTRA?
Classic generic-entry risk is low because entry has already occurred. The relevant risk is reverse: supply contraction or manufacturer withdrawal.
Commercial risks include:
- API supply disruption.
- Manufacturing-site remediation.
- Low margins causing portfolio exits.
- Hospital contract losses.
- Shortages in oral suspension or injectable presentations.
- Increased regulatory scrutiny of sterile manufacturing.
- Resistance-driven reduction in prescribing.
- Substitution by newer or better-tolerated agents.
A mature generic can remain clinically important while becoming financially unattractive to manufacturers. Low prices leave limited room to absorb higher labor, compliance, freight, or active-ingredient costs.
What is the outlook for SEPTRA’s revenue?
SEPTRA’s brand-specific revenue trajectory is likely flat to declining because branded sales have been displaced by generic sulfamethoxazole/trimethoprim. The broader molecule-market trajectory is more stable.
Base case
Volume remains durable, while pricing stays low. Revenue grows only through population demand, periodic supply shortages, or price normalization after temporary disruption.
Downside case
Resistance, antimicrobial stewardship, and supplier exits reduce routine use. Oral suspension and injectable products experience intermittent shortages, but the category does not disappear.
Upside case
A supply shortage among competing manufacturers produces temporary price increases or share gains for an available supplier. This would be a supply-driven event rather than evidence of renewed brand strength.
The highest-value commercial opportunities are likely in reliable supply, institutional contracts, specialty formulations, and manufacturing efficiency rather than in a new branded SEPTRA launch.
What patent litigation or settlement agreements affect SEPTRA?
No major current patent-litigation or settlement framework defines the mature SEPTRA market in the way that litigation affects newer branded medicines. Historical settlements, if any, would have limited relevance to present-day competition because the core product is already genericized.
For diligence purposes, litigation review should focus on the specific manufacturer and dosage form. Potential issues may involve product liability, manufacturing compliance, labeling, supply contracts, or procurement disputes rather than foundational patent litigation.
What geographic markets remain commercially relevant?
The United States remains a large and highly competitive generic market. Europe and other regulated markets also use TMP-SMX, but product names, reference products, reimbursement rules, and approval pathways differ.
| Region |
Commercial characteristics |
| United States |
Mature ANDA market, low pricing, fragmented supply |
| European Union |
National reimbursement and procurement systems; product availability varies |
| Canada |
Generic competition and provincial reimbursement influence |
| Emerging markets |
Wider use may persist, but pricing and quality controls vary |
| Hospital markets |
Contract-driven purchasing and shortage sensitivity |
Foreign patent status should not be inferred from U.S. expiry. In practice, the commercial barriers in most jurisdictions are regulatory approval, local registration, quality compliance, and distribution rather than active core patents.
How strong is the SEPTRA patent estate?
The patent estate is weak as a current commercial defense. SEPTRA has:
- No meaningful remaining composition-of-matter exclusivity.
- No practical branded pricing power.
- Extensive generic substitution.
- Limited ability to block standard dosage-form competitors.
- Potentially relevant but narrow technical rights around specific formulations or processes.
Its strength lies in clinical familiarity and established demand, not intellectual property.
Key Takeaways
- SEPTRA is the historical brand associated with sulfamethoxazole/trimethoprim.
- The core product has been genericized for decades.
- No current core patent estate is expected to block standard U.S. generic entry.
- FDA-regulated tablets, oral suspension, and injectable products remain commercially relevant, but availability varies by manufacturer.
- Brand-specific revenue is not reliably disclosed and is likely small relative to the broader generic molecule market.
- Generic TMP-SMX demand is durable but mature, with limited pricing power.
- Resistance, antimicrobial stewardship, adverse effects, and supply disruptions shape the market more than patent expiry.
- The main commercial opportunity is dependable manufacturing and distribution, not brand relaunch.
- The principal risk is supplier withdrawal or shortage rather than a classic Paragraph IV challenge.
Frequently Asked Questions
Is SEPTRA still available as a branded drug?
Branded availability is limited and market-dependent. U.S. dispensing is primarily based on generic sulfamethoxazole/trimethoprim products.
Is SEPTRA the same as sulfamethoxazole/trimethoprim?
Yes. SEPTRA refers to the brand associated with the fixed-dose combination of sulfamethoxazole and trimethoprim.
Does SEPTRA have active U.S. patents?
The core combination and conventional dosage forms are long genericized. Any potentially active rights would be product-specific and more likely to concern formulation, manufacturing, or packaging.
Can a generic company launch TMP-SMX without SEPTRA approval?
A company must obtain FDA approval for its own product, generally through an ANDA or another applicable pathway. It does not need authorization from the historical SEPTRA brand holder to market an approved generic.
Is SEPTRA a good pharmaceutical licensing target?
The mature molecule is generally a low-value licensing target. The stronger opportunities are in supply reliability, specialized dosage forms, institutional distribution, or manufacturing assets.
References
-
U.S. Food and Drug Administration. (2023). Sulfamethoxazole and trimethoprim prescribing information. FDA labeling database.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
Infectious Diseases Society of America. (2011). IDSA guidelines for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical Infectious Diseases, 52(3), e18-e55.
-
Centers for Disease Control and Prevention. (2024). Antibiotic resistance threats and antimicrobial stewardship resources. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. Center for Drug Evaluation and Research.
